Press Release

Ortho Clinical Diagnostics Named Finalist in Fast Company’s 2021 World Changing Ideas Awards

Raritan, NJ

May 4, 2021

Ortho’s COVID-19 Solutions Recognized in Pandemic Response Category


Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, has been named a finalist in Fast Company’s 2021 World Changing Ideas Awards for its VITROS® COVID-19 testing solutions, which help labs meet the demands of the pandemic with reliable mass-scale testing options.


Fast Company’s 2021 World Changing Ideas Awards showcase 33 winners and more than 400 finalists from businesses, policies, projects, and concepts across the world that are actively engaged and deeply committed to pursuing innovation. Ortho’s VITROS® Anti-SARS-CoV-2 Total and IgG Antibody tests and VITROS® SARS-CoV-2 Antigen Test were recognized in the Pandemic Response category.

“When the world needed highly accurate COVID-19 diagnostic solutions, Ortho leveraged over 80 years of experience and launched a solution in less than three weeks that had immediate utility for backlogged labs and communities across the world,” said Chockalingam Palaniappan, PhD, chief innovation officer, Ortho Clinical Diagnostics. “We are honored to be recognized by Fast Company, and will continue to deliver tools that will ultimately help end this pandemic—Because Every Test Is A Life.™”

To learn more about Ortho’s COVID-19 solutions, visit


About Ortho’s VITROS® COVID-19 Testing Solutions

Authorized for use in the U.S. in January 2021, Ortho’s VITROS® SARS-CoV-2 Antigen Test offers reliable detection of acute COVID-19 infection with high sensitivity and specificity. With utility for mass-scale testing and same-day results for labs, Ortho’s antigen test can be processed at a rate of up to 130 tests per hour on a single analyzer, bolstering the ability of hospitals and reference labs to address testing backlogs, supply shortages, and delayed results that have undermined previous testing efforts. The VITROS® SARS-CoV-2 Antigen Test also offers a practical and cost-effective testing alternative to polymerase-chain reaction (PCR) tests, which, while highly accurate, can be expensive and require long processing times during testing surges.


Ortho’s Total Antibody Test, designed to indicate recent or prior SARS-CoV-2 infection, detects all COVID-19 related antibodies (IgA, IgM and IgG). The company’s COVID-19 IgG antibody test detects the IgG antibody, which appears in a patient's blood in the later phase of infection and remains elevated even after recovery. Offering high sensitivity and specificity, both the Total and IgG tests – which have FDA EUA and CE Mark – provide public health leaders with an exceptional tool in tracking viral community spread, bolstering serological surveillance efforts, and managing patient treatment pathways.


Questions from laboratories, health care providers, or government officials regarding Ortho’s COVID-19 solutions can be directed to: For more information visit:


The VITROS Anti-SARS-CoV-2 Total and IgG Antibody Tests and the VITROS SARS-CoV-2 Antigen Test have not been cleared or approved by the U.S Food and Drug Administration (FDA). They have been authorized by the FDA under an Emergency Use Authorization (EUA) and testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate- or high-complexity tests. The VITROS antibody tests have been authorized only for the detection of either total or IgG antibodies from SARS-CoV-2, not for any other viruses or pathogens, and results should not be used as the sole basis for diagnosis. The VITROS antigen test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.


About the World Changing Ideas Awards

World Changing Ideas is one of Fast Company’s major annual awards programs and is focused on social good, seeking to elevate finished products and brave concepts that make the world better. A panel of judges from across sectors choose winners, finalists, and honorable mentions based on feasibility and the potential for impact. With the goals of awarding ingenuity and fostering innovation, Fast Company draws attention to ideas with great potential and helps them expand their reach to inspire more people to start working on solving the problems that affect us all.


About Ortho Clinical Diagnostics

Ortho Clinical Diagnostics (NASDAQ: OCDX) is one of the world’s largest pure-play in vitro diagnostics (IVD) companies.


More than 800,000 patients across the world are impacted by Ortho’s tests each day. Because Every Test is a Life™, Ortho provides hospitals, hospital networks, clinical laboratories, and blood banks around the globe with innovative IVD technologies to ensure that test results are fast, accurate and reliable. Ortho helps its customers enhance clinical outcomes, improve efficiency, overcome staffing challenges and reduce costs.


As a pioneering leader in IVD for more than over 80 years, Ortho launched the first product to determine Rh+ or Rh- blood type, developed the world’s first tests for the detection of antibodies against HIV and hepatitis C, introduced patented dry-slide technology, and was the first company to receive U.S. Food and Drug Administration (FDA) authorization for a high-volume antibody and antigen test for COVID-19. 


The company is known industry-wide for Ortho Care™, its holistic customer support program which ensures technical, field and remote service and inventory support in more than 130 countries and territories.

Press contact:

For media inquiries please contact

Ortho Media Relations
Ortho Clinical Diagnostics